Literature DB >> 15123854

Antiretrovirals, part 1: overview, history, and focus on protease inhibitors.

Gary H Wynn1, Michael J Zapor, Benjamin H Smith, Glenn Wortmann, Jessica R Oesterheld, Scott C Armstrong, Kelly L Cozza.   

Abstract

This column is the first in a series on HIV/AIDS antiretroviral drugs. This first review summarizes the history of HIV/AIDS and the development of highly active antiretroviral therapy (HAART) and highlights why it is important for non-HIV specialists to know about these drugs. There are four broad classes of HIV medications used in varying combinations in HAART: the protease inhibitors, nucleoside analogue reverse transcriptase inhibitors, the non-nucleoside reverse transcriptase inhibitors, and cell membrane fusion inhibitors. This paper reviews the mechanism of action, side effects, toxicities, and drug interactions of the protease inhibitors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15123854     DOI: 10.1176/appi.psy.45.3.262

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  9 in total

Review 1.  Emerging drug targets for antiretroviral therapy.

Authors:  Jacqueline D Reeves; Andrew J Piefer
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.

Authors:  Mark A Boyd; Andrew M Hill
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  HIV-1 Alters Intestinal Expression of Drug Transporters and Metabolic Enzymes: Implications for Antiretroviral Drug Disposition.

Authors:  Olena Kis; Sumathi Sankaran-Walters; M Tozammel Hoque; Sharon L Walmsley; Satya Dandekar; Reina Bendayan
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

4.  Rural AIDS diagnoses in Florida: changing demographics and factors associated with survival.

Authors:  Mary Jo Trepka; Theophile Niyonsenga; Lorene M Maddox; Spencer Lieb
Journal:  J Rural Health       Date:  2013-01-14       Impact factor: 4.333

5.  Non-injection drug use and HIV disease progression in the era of combination antiretroviral therapy.

Authors:  Aaron M Kipp; Andrew J Desruisseau; Han-Zhu Qian
Journal:  J Subst Abuse Treat       Date:  2011-02-24

6.  Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions.

Authors:  Olena Kis; Jason A Zastre; Md Tozammel Hoque; Sharon L Walmsley; Reina Bendayan
Journal:  Pharm Res       Date:  2012-12-07       Impact factor: 4.200

7.  Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen.

Authors:  Anali Conesa-Botella; Eric Florence; Lutgarde Lynen; Robert Colebunders; Joris Menten; Rodrigo Moreno-Reyes
Journal:  AIDS Res Ther       Date:  2010-11-23       Impact factor: 2.250

Review 8.  Phytochemicals from Plant Foods as Potential Source of Antiviral Agents: An Overview.

Authors:  Tapan Behl; Gabriele Rocchetti; Swati Chadha; Gokhan Zengin; Simona Bungau; Arun Kumar; Vineet Mehta; Md Sahab Uddin; Gaurav Khullar; Dhruv Setia; Sandeep Arora; Kouadio Ibrahime Sinan; Gunes Ak; Predrag Putnik; Monica Gallo; Domenico Montesano
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-19

Review 9.  Management of Antiretroviral Therapy with Boosted Protease Inhibitors-Darunavir/Ritonavir or Darunavir/Cobicistat.

Authors:  Ruxandra-Cristina Marin; Tapan Behl; Nicoleta Negrut; Simona Bungau
Journal:  Biomedicines       Date:  2021-03-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.